2Ciardiello F, Tortora C. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74. 被引量:1
3Zwick E, Bange J, UIIrich A. Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161- 73. 被引量:1
4Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2009; 9: 221-25. 被引量:1
5Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010; 16: 37-45. 被引量:1
6Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Bio12007; 19: 117-23. 被引量:1
7Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 2010; 70: 3857-60. 被引量:1
8Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromes when good receptors turn bad. Trends Genet 2000; 16: 265 - 71. 被引量:1
9Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 17: 1343-52. 被引量:1